Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable several functions, including cholesterol-protein transferase activity; patched binding activity; and very-low-density lipoprotein particle binding activity. Acts upstream of or within oligodendrocyte differentiation; regulation of oligodendrocyte progenitor proliferation; and striated muscle cell development. Predicted to be located in several cellular components, including Golgi membrane; endoplasmic reticulum membrane; and extracellular region. Predicted to be active in extracellular space. Is expressed in axis; central nervous system; cranium; gut; and notochord. Human ortholog(s) of this gene implicated in acrocapitofemoral dysplasia; brachydactyly type A1; retinopathy of prematurity; and syndactyly type 1. Orthologous to human IHH (Indian hedgehog signaling molecule). [provided by Alliance of Genome Resources, Feb 2025]